STOCKWATCH: Currencies continue to confound earnings
This article was originally published in Scrip
It is strange to think that while we work our way through the tail-end of the full-year 2014 earnings season, we are only about a month away from the start of next reporting period. The big issue that emerged at the start of the last earning season – the effects of foreign currency translations – is likely to worsen, particularly for those companies that couldn't bring themselves to give 2015 guidance in their last earnings announcement.
You may also be interested in...
Can the development of coronavirus vaccines and therapeutics reverse the demonization of the pharmaceutical sector brought about by drug price increases?
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.
A complete response letter from the FDA knocked Intercept’s stock price for six, but perhaps the FDA is sending wider messages about NASH.